Floatz logo

BARDOXOLONE METHYL ESTER

Pulmonary Hypertension

BiogenSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Pulmonary Hypertension cohort.

Asset / SponsorPhaseRating
Sildenafil
Duke University
Phase 4BB
Epoprostenol
National Center for Research Resources (NCRR)
Phase 4BB
Tadalafil
Ochsner Health System
Phase 4B
Tadalafil
Ochsner Health System
Phase 4B
TREPROSTINIL PHOSPHATE
University of California, San Diego
Phase 3B

View all 31 →

Same molecule, other indications

BARDOXOLONE METHYL ESTER is also rated in:

interstitial lung diseaseDormant
B
Indicative ·
57 / 100
View asset →
pulmonary arterial hypertensionDormant
B
Indicative ·
57 / 100
View asset →
idiopathic interstitial pneumoniaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →